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Background: The TNF family ligand EDA1 is required for development of hair, teeth, and many glands.
Results:Mouse fetuses exposed to anti-EDA antibodies develop a permanent ectodermal dysplasia.
Conclusion:Monoclonal anti-EDA antibodies block EDA at stoichiometric ratio in vitro and in vivo.
Significance: Down-modulation of EDA has useful research and potentially therapeutic applications.
Development of ectodermal appendages, such as hair, teeth,
sweat glands, sebaceous glands, and mammary glands, requires
the action of the TNF family ligand ectodysplasin A (EDA).
Mutations of theX-linkedEDA gene cause reduction or absence
of many ectodermal appendages and have been identified as a
cause of ectodermal dysplasia in humans, mice, dogs, and cattle.
We have generated blocking antibodies, raised in Eda-deficient
mice, against the conserved, receptor-binding domain of EDA.
These antibodies recognize epitopes overlapping the receptor-
binding site and prevent EDA from binding and activating
EDAR at close to stoichiometric ratios in in vitro binding and
activity assays. The antibodies block EDA1 and EDA2 of both
mammalian and avian origin and, in vivo, suppress the ability of
recombinant Fc-EDA1 to rescue ectodermal dysplasia in Eda-
deficient Tabby mice. Moreover, administration of EDA block-
ing antibodies to pregnantwild typemice induced in developing
wild type fetuses amarked andpermanent ectodermal dysplasia.
These function-blocking anti-EDA antibodies with wide cross-
species reactivity will enable study of the developmental and
postdevelopmental roles of EDA in a variety of organisms and
open the route to therapeutic intervention in conditions in
which EDAmay be implicated.
The surface ectoderm of the embryo acquires a range of
appendages over the course of its development that go on to
carry out very diverse functions in the adult. The sites of
appendage formation are firstmarked by activation of theWnt/
-catenin signaling pathway in the embryonic skin epithelium
(1–3). The action of theTNF family ligand EDA2 on its receptor
EDAR, a target gene ofWnt signaling, is required shortly there-
after at least for sweat glands and some hair types, to stimulate
the transcription factor NF-B, itself necessary for the forma-
tion of morphologically distinct cellular condensates called
placodes (3, 4). Some placodes, such as those of guard hair
developing at embryonic day (E) 14.5, are fully dependent on
EDA-EDAR interactions and NF-B for their formation,
whereas others, such as those of undercoat hair developing at
around birth, can form in the absence of EDA but produce
morphologically abnormal hair (4). In the skin, a pattern of
regularly spaced placodes forms as a result of sustained EDAR
activation within placodes that induces strong inhibitory sig-
nals at the placode periphery. Inhibitory signals aremediatedby
bone morphogenetic protein-mediated repression of EDAR
expression (2). Placodes themselves escape the inhibitory actionof
bone morphogenetic proteins by producing secreted bone mor-
phogenetic protein inhibitors, presumably with short ranges of
action (2, 5).
After placode formation, EDA continues to play roles in the
development and maintenance of ectodermal structures. For
example, in tooth buds after the placode stage, EDAR is
expressed in the enamel knots, which are nonproliferating sig-
naling centers that guide the shaping of the tooth crown (6, 7).
The observation of morphological abnormalities in hair from
Eda-deficient mice further suggests a role for EDA in the regu-
lation of hair morphogenesis at a postplacodal stage (4). In par-
ticular, localization of Shh expression by Wnt and EDA affects
axial polarity and shape of hairs (8). Finally, postdevelopmental
roles for EDA in controlling sebaceous gland size and the tim-
ing of the transition from the anagen to the catagen phase dur-
ing the hair cycle have been proposed (9, 10), in line with the
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observation that EDA remains expressed in the adult hair folli-
cle and in skin glands (11). In general, postdevelopmental roles
of EDA remain poorly studied, in part because of the lack of
suitable reagents allowing for long term pharmacological mod-
ulation of EDA activity in adults.
EDA is a membrane-bound TNF family member that must
be proteolytically processed to a soluble form to display activity
on neighboring EDAR-positive cells (12). EDA contains an
intracellular domain with no demonstrated function, and an
extracellular domain displaying two overlapping furin consen-
sus cleavage sites, a short basic proteoglycan-binding region, a
collagen domain with a kink-introducing interruption in the
middle, followed by the TNF homology domain (amino acids
245–391 in human EDA1) responsible for homotrimerization
and receptor binding (13, 14). Mutations destroying the furin
consensus sequence, the collagen domain, or the TNF homol-
ogy domain can all cause X-linked hypohidrotic ectodermal
dysplasia (13), a genetic deficiency characterized by reduced
numbers and functionality of various ectoderm-derived struc-
tures (15–17). Milder mutations that decrease but do not com-
pletely abolish EDA-EDAR interactions correlate with selective
tooth agenesis, in which teeth are affected but other append-
ages are spared from clinically relevant defects (18).
EDA transcripts are produced as two main functional splice
variants, encoding EDA1 and EDA2, which differ by two amino
acid residues. This minor sequence difference is sufficient to
switch the receptor binding specificity from EDAR for EDA1 to
XEDAR for EDA2 (19). The EDA1-EDAR axis plays a predom-
inant role in the development of skin-derived structures,
whereas EDA2 and XEDAR, also known as EDA2R, have little
or no role in this respect (20–24). XEDAR is closely related to
the orphan receptor TROY, and an NF-B-independent role
for TROY in hair formation was identified in mice deficient for
both TROY and EDA (25). TROY may bind to lymphotoxin 
(26), but our laboratory did not detect this interaction (27).
The TNF homology domain of EDA (from Gln-247 to Ser-
391) ismore conserved than that of any otherTNF familymem-
ber, with human EDA being 100 and 98% identical to mouse
and chicken EDA, respectively. Consistent with the high degree
of sequence conservation, mouse EDA was found to be func-
tionally active in rescuing scale formation in a teleost fish (28).
In this study, we describe two monoclonal antibodies raised
inEda-deficientmice that efficiently inhibit EDA1 activity both
in vitro and in vivo. These antibodies will be useful for immu-
nodetection of EDA protein and to explore the developmental
and homeostatic roles of EDA signaling in birds andmammals.
EXPERIMENTAL PROCEDURES
Animals—White-bellied agouti B6CBAa Aw-J/A-EdaTa/J
Tabby mice (000314; Jackson Laboratory) and their wild type
controls were handled according to Swiss Federal Veterinary
Office guidelines, under the authorization of the Office
Vétérinaire Cantonal du Canton de Vaud (authorization
1370.5 to P. S.).
Plasmids and Recombinant Proteins—Plasmids used in this
study were reported before (14, 27, 29, 30) or constructed using
standard molecular biology techniques (Table 1). A fully
human form of Fc-EDA1 was kindly provided by Edimer Phar-
maceuticals (Cambridge, MA).
Generation and Purification of Anti-EDA Monoclonal
Antibodies—Eda-deficient Tabby mice were immunized with
Fc-EDA1 as described previously for EDAR-Fc (30). Cells har-
vested frommice positive for anti-EDA antibodies were used to
generate hybridoma. Hybridoma supernatants were tested for
their ability to recognize coated FLAG-EDA1 by ELISA and for
their ability to block the binding of FLAG-EDA1 to coated
EDAR-Fc in the ELISA format described under “ELISA.” Posi-
tive clones were subcloned by limiting dilution and then slowly
adapted to serum-containing DMEM or to serum-free Opti-
MEMmedium (Invitrogen). Antibodies were purified from con-
ditioned supernatants of hybridoma grown in DMEM containing
10% low Ig fetal calf serum (Invitrogen) or Opti-MEM by affinity
chromatography on protein G-Sepharose (GE Healthcare). Anti-
EDAmonoclonal antibody Renzo-2 and anti-APRIL monoclonal
TABLE 1
Plasmids used in this study
Signal, MAIIYLILLFTAVRG; Ig signal, METDTLLLWVLLLWVPGSTG; FLAG, DYKDDDDK; linker, RSPQPQPKPQPKPEPEGS; PreSci, LEVLFQGP; aa, amino acids.
Plasmid Designation Protein encoded Vector Figure(s)
ps515 EGFP Enhanced green fluorescent protein PCR3 5A and 6
ps548 FLAG-EDA1 Signal-FLAG-GPGQVQLQVD-mEDA1 (aa 245–391) PCR3 5B
ps930 hEDAR-Fc hEDAR (aa 1–183)-VD-hIgG1 (aa 245–470) PCR3 5B
ps1196 Fc-hBAFF Signal-LD-hIgG1 (aa 245–470)-linker-PreSci-GSLQ-hBAFF (aa 137–285) PCR3 4
ps1235 Fc-EDA2 Signal-LD-hIgG1 (aa 245–470)-linker-LQVD-hEDA2 (aa 245–389) PCR3 5A and 6
ps1236 Fc-EDA1 Signal-LD-hIgG1 (aa 245–470)-linker-LQVD-hEDA1 (aa 245–391) PCR3 4
ps1431 hEDAR-GPI hEDAR (aa 1–183)-VD-hTRAILR3 (aa 157–259) PCR3 5A and 6
ps1432 hXEDAR-GPI Ig signal-DVT-hXEDAR (aa 1–134)-VD-hTRAILR3 (aa 157–259) PCR3 5A and 6
ps1434 hTROY-GPI hTROY (aa 1–168)-VD-hTRAILR3 (aa 157–259) PCR3 6
ps1661 Fc-PS-EDA1 Signal-LD-hIgG1 (aa 245–470)-linker-PreSci-GSLQVD-EDA1 (aa 245–391) PCR3 5A and 6
ps1938 Fc-EDA1 Signal-hIgG1 (aa 245–470)-hEDA1 (aa 238–391) PCR3 2, 3, 5C, and 8
ps2199 hEDAR:Fas hEDAR (aa 1–183)-VD-hFas (aa 169–335) pMSCV 5C
ps2290 chEDAR-GPI chEDAR (aa 1–183)-VD-hTRAILR3 (aa 157–259) PCR3 5A and 6
ps2303 Fc-chEDA1 Signal-LD-hIgG1 (aa 245–470)-linker-LQNSG-chEDA1 (aa 207–353) PCR3 5A and 6
ps2323 chTROY-GPI chTROY (aa 1–167)-VD-hTRAILR3 (aa 157–259) PCR3 6
ps2335 Fc-chEDA2 Signal-LD-hIgG1 (aa 245–470)-linker-LQ-chEDA1 (aa 207–351) PCR3 5A and 6
ps2340 chXEDAR-GPI Signal-LE-chXEDAR (aa 2–137)-GSVD-hTRAILR3 (aa 157–259) PCR3 5A and 6
ps2485 Fc-EDA1 V365A Signal-LD-hIgG1 (aa 245–470)-linker-LQVD-hEDA1 (aa 245–391; V365A) PCR3 4
ps2486 Fc-EDA1 S374A Signal-LD-hIgG1 (aa 245–470)-linker-LQVD-hEDA1 (aa 245–391; S374R) PCR3 4
ps2487 Fc-EDA1 Q358E Signal-LD-hIgG1 (aa 245–470)-linker-LQVD-hEDA1 (aa 245–391; Q358E) PCR3 4
ps2589 Fc-EDA1 D316G Signal-LD-hIgG1 (aa 245–470)-linker-LQVD-hEDA1 (aa 245–391; D316G) PCR3 4
ps2590 Fc-EDA1 T338M Signal-LD-hIgG1 (aa 245–470)-linker-LQVD-hEDA1 (aa 245–391; T338M) PCR3 4
ps2826 Fc-hAPRIL Signal-LD-hIgG1 (aa 245–470)-linker-LQ-hAPRIL (aa 98–233) PCR3 2, B and C
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antibody Aprily2 are commercially available (Enzo Life Sciences).
Antibodies (1mg)were biotinylated inAmiconUltra 10-kDa pro-
tein concentrators (Millipore) in 300 l of 0.1 M sodium borate
buffer, pH 8.8, with 10 l of 10 mg/ml EZ-LinkTM Sulfo-NHS-
SS-biotin (Pierce) in DMSO for 1 h at room temperature. The
reaction was stopped with 10 l of 1 M NH4Cl, and buffer was
exchanged for PBS (10 mM sodium-potassium phosphate, 140
mM NaCl, pH 7.2) by diafiltration.
Transfections—HEK 293T cells were grown in DMEM, 10%
fetal calf serum and transfected by the calcium phosphate
method. Cells were grown for 7 days in serum-free Opti-MEM
medium (Invitrogen) for the production of human or chicken
Fc-EDA1 and 2 or for 48 h in complete medium for surface
expression of receptors-TRAILR3 fusion proteins.
ELISA—For the detection of anti-EDA antibodies, ELISA
plates were coated with FLAG-EDA at 1 g/ml, blocked, and
revealed with anti-EDA antibodies (adequately diluted serum
of EDA immunized Tabby mice, hybridoma supernatants, or
purified antibodies) followed by a peroxidase-coupled goat
anti-mouse IgG (1/5000) (Jackson ImmunoResearch). For iso-
type determination, ELISAplateswere coatedwith 0.2g/ml of
FLAG-EDA1 and revealed with anti-EDA antibodies followed
by peroxidase-coupled antibodies against the heavy chain of
mouse IgG1, IgG2a, IgG2b, IgG3, or IgM (all from Jackson
ImmunoResearch). For epitope mapping, ELISA plates were
coated with 1 g/ml of purified Fc-EDA1 or with 1 g/ml of
Fc-EDA1 carrying point mutations D316G, T338M, Q358E,
V365A, and S374R and revealed with anti-EDA antibodies at 1
g/ml followed by peroxidase-coupled goat anti-mouse IgG
(1/8000) (Jackson ImmunoResearch). For the differential rec-
ognition of plate-bound versus native Fc-EDA1, ELISA plates
were coated either directly with Fc-EDA1 at 1 g/ml, or with a
goat anti-human Ig antibody (Jackson ImmunoResearch 109-
005-098) at 5 g/ml, followed, after blocking, by Fc-EDA1 at 1
g/ml. Plates were revealed with serial dilutions of anti-EDA
antibodies, followed by peroxidase-coupled goat anti-mouse
IgG (1/8000). For the competition ELISA-like assay, plates were
coated with 1 g/ml of EDAR-Fc and revealed with titrated
amounts of FLAG-EDA1 that had been preincubated for 1 h
with buffer or with 125 ng/ml of anti-EDA antibodies. Bound
FLAG-EDA1 was revealed with 0.5 g/ml of biotinylated anti-
FLAGM2 antibody (Sigma) and peroxidase-coupled streptavi-
din (1/5000). For the screening of hybridoma supernatants, an
amount of FLAG-EDA1 giving maximal, nonsaturating signal
was preincubated in hybridoma supernatants for 1 h prior to
addition on EDAR-Fc-coated ELISA plates. For the sandwich
ELISA, ELISA plates were coated with 5 g/ml of anti-EDA
antibodies or 5 g/ml of goat anti-human IgG (Jackson Immu-
noResearch 109-005-098). The plates were saturated with 4%
powdered skimmed milk and 0.5% Tween 20 in PBS. Titrated
amounts of Fc-EDA1 were added (in saturation buffer diluted
1/10 in PBS, in the presence or absence of 50% mouse or 50%
human serum) and revealed either with 1g/ml of biotinylated
anti-EDA antibodies followed by peroxidase-coupled streptavi-
din (1/5000) or with peroxidase-coupled goat anti-human IgG
(1/5000) (Jackson ImmunoResearch 109-035-003).
SDS-PAGE, Western Blot, and Native Gel Electrophoresis—
Anti-EDA antibodies (10 g/lane) were analyzed by SDS-
PAGE under reducing conditions followed by Coomassie Blue
staining. To test the ability of anti-EDA antibodies to recognize
denatured EDA1, 50 or 200 ng of Fc-EDA1 and 500 ng of Fc-
APRIL were denatured for 3 min at 70 °C in SDS-PAGE sample
buffer containing 30 mM dithiothreitol and revealed by West-
ern blotting with the various anti-EDA antibodies at 1 g/ml,
followed by peroxidase-coupled anti-mouse antibody (1:8000)
and ECL reagent (GE Healthcare).
Sequencing of Anti-EDA Antibodies—RNA was extracted
from hybridoma cells with an RNAeasy kit (Qiagen) according
to the manufacturer’s guidelines. cDNA was prepared by
reverse transcription with Ready-To-Go T-Primed first strand
kit (GE Healthcare). Variable sequences of the heavy and light
chains were amplified by PCR as described (31, 32). PCR prod-
ucts were sequenced on both strands. Sequences were analyzed
for gene usage using the IMGT sequence alignment software.
FACS Analyses—293T cells co-transfected with EGFP and
receptor-GPI expression plasmids were stained with human or
chicken Fc-EDA1 or Fc-EDA2 in conditioned serum-free
medium, or with anti-TRAILR3 antibody essentially as described
before (27). In addition, Fc-EDAs in serum-free supernatants of
transfected 293T cells (25 l) were preincubated for 1 h at room
temperature in the presence or absence of 2 g of anti-EDA
antibodies prior to staining. Cells were analyzed using a
FACScan flow cytometer (Becton Dickinson) and FlowJo
software (TreeStar, Ashland, OR).
In Vitro Cytotoxicity Assays—Fas-deficient hEDAR-Fas Jur-
kat cells have been described before (14). These reporter cells
were exposed to increasing amounts of Fc-EDA1 that had been
preincubated with fixed concentrations of anti-EDA antibod-
ies. The cytotoxicity assay using EDAR-Fas Jurkat cells was per-
formed as described for FasL on Jurkat cells (33).
Administration of Proteins to Eda-deficient and Wild Type
Animals—Eda-deficient Tabby pups were treated on the day of
birth, as described, with one intraperitoneal injection of Fc-
EDA1 at 2.5mg/kg thatwas preincubated for 1 hwith anti-EDA
antibodies EctoD1 (n 3) or EctoD2 (n 4) at 10 mg/kg (30).
Examination of tail hairs and sweat tests were performed at
weaning. Pregnant WT mice (one mouse/antibody) were
treated intravenously every second to fourth daywith anti-EDA
antibodies at 4mg/kg throughout pregnancy. After birth, treat-
ment was continued for 2–3 weeks in half of the pups (n 2, 3,
and 4 for EctoD1, EctoD2, and EctoD3, respectively) with intra-
peritoneal injections at the same dose and frequency but was
interrupted in the other half of the pups (n  2, 3, and 5 for
EctoD1, EctoD2, and EctoD3, respectively). Offspring were
analyzed at weaning (3 weeks) for external phenotypes and
sweat tests and at 1 month of age for histology and tooth anal-
ysis, essentially as described (34). Age-matched wild type and
Eda-deficient Tabby mice were similarly analyzed for compar-
ison. Tracheal glands were detected by Alcian blue staining
(35). Skulls were prepared by digesting soft tissues for 6 h at
55 °C with proteinase K (20 l of proteinase K (Roche Applied
Science) in 8 ml of 10 mM Tris, pH 8, 5 mM EDTA, 100 mM
NaCl, 0.5%SDS) and then rinsingwithwater. Remaining tissues
were removed with fine tweezers; jaws were placed in 20% eth-
anol for 2 days, incubated in 3% H2O2 for 16 h, rinsed with
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water, dried, and photographed with a M205FA stereomicro-
scope (Leica).
RESULTS
Generation of Anti-EDA Antibodies That Recognize Surface-
exposed Epitopes of EDA—The extracellular, receptor-binding
region of EDA is identical at the amino acid level between
human and mouse. To generate blocking anti-EDA antibodies,
Eda-deficient Tabby mice were immunized with an active
recombinant form of EDA1, Fc-EDA1. In this strain, exon 1 of
the Eda gene is deleted such that these animals express no EDA
protein (36). Though only weak titers of anti-EDA antibodies
were detected in immunized mice, their sera displayed EDA
blocking activity (data not shown). Three EDA-specific
hybridoma were obtained, subcloned, and established. Anti-
bodies secreted by these hybridoma, named EctoD1, EctoD2,
and EctoD3, were IgG1 with distinct variable gene usage for
both the heavy and light chains (Table 2 and Fig. 1). Purified
antibodies (Fig. 2A) were tested for their recognition of dena-
tured and native EDA1. EctoD1 and EctoD2 weakly recognized
reduced Fc-EDA byWestern blot, whereas EctoD3 produced a
more convincing signal on Fc-EDA1, but not on an excess of the
control protein Fc-APRIL. This signal remained, however,
weaker than that obtained with the commercial anti-EDA anti-
body Renzo2 (Fig. 2B). An ELISA assay was performed in which
the antigen Fc-EDA1 was either coated directly to the plate, a
process that partially denatures proteins, or else was captured
via its Fc portion to maintain its native structure. Renzo2 dis-
played better recognition of coated rather than captured Fc-
EDA1, suggesting that it preferentially recognized an epitope in
the denatured protein (Fig. 2C). In contrast, EctoD1, EctoD2,
and EctoD3 recognized both coated and captured Fc-EDA1
with similar signal intensities, suggesting that they recognize
surface-exposed epitopes in EDA1 (Fig. 2C). Taken together,
these results suggest that Renzo2 may recognize a linear, par-
tially buried epitope, whereas EctoD1, EctoD2, and EctoD3
preferentially bind to surface epitopes that may not be linear in
the primary sequence.
Sensitive Detection of Fc-EDA by Sandwich ELISA—Prenatal
or neonatal Fc-EDA1 treatment has successfully been used in
different animal models of hypohidrotic ectodermal dysplasia
to improve several aspects of the disease (34, 37). Because Fc-
EDA1 is currently being tested in clinical trials, its sensitive
detection is important to enable monitoring of its pharmaco-
logic parameters. Renzo2, EctoD2, and EctoD3 were tested in
various combinations for their ability to recognize Fc-EDA1 in
a sandwich ELISA.Whereas Renzo2was relatively inefficient at
both capture and revelation, EctoD2 and EctoD3 detected Fc-
EDA1 at less than 1 ng/ml and compared favorably to other
sandwich detection systems based on recombinant EDAR or
anti-Fc reagents (Fig. 3, A and B). Importantly, sensitive detec-
tion of Fc-EDA1 was readily achieved in the presence of 50%
human serum and only slightly reduced in the presence of 50%
mouse serum (Fig. 3C). Thus, EctoD2 at capture and EctoD3 at
revelation form an efficient pair of antibodies for the sensitive
detection of Fc-EDA1.
Anti-EDAAntibodies EctoD2 and EctoD3 Recognize Epitopes
That Overlap with the Receptor-binding Site on Two Adjacent
EDA Monomers—The recognition of Fc-EDA1 by anti-EDA
antibodies was tested on a panel of EDA1 mutations occurring
in patients with nonsyndromic tooth agenesis. These mutants
FIGURE 1.Amino acid sequences of anti-EDA antibodies. A, sequences of light chains. Complementarity-determining regions (CRD) are boxed. B, sequences
of heavy chains. Black arrows indicate boundaries of sequences coded by the variable (V), diversity (D), joining (J), and constant (C) genes. N, sequence coded
by random addition of nucleotides.
TABLE 2
Characteristics of anti-EDAmonoclonal antibodies
IGHV and IGLV, immunoglobulin heavy and light chains, respectively, variable region genes likely used in the antibody; Block EDA1, able to prevent the binding of EDA1
to EDAR; Block EDA2, able to prevent the binding of EDA2 to XEDAR; mAb/EDA1 ELISA, number of anti-EDA antibody molecules required to block half of the activity
of one trimeric FLAG-EDA1molecule in the ELISAbinding assay;mAb/EDA1 reporter, number of anti-EDA antibodymolecules required to block half of the killing activity
of one hexameric Fc-EDA1 molecule in the reporter cell assay using EDAR, Fas-expressing Jurkat cells.
Anti-EDA IGHV gene IGLV gene Iso-type Block EDA1 Block EDA2 mAb/EDA1 ELISA mAb/EDA1 reporter
EctoD1 1–26 3–4 IgG1 No No NA NA
EctoD2 5–9 3–5 IgG1 Yes Yes 1.4 4.9
EctoD3 1–81 3–12 IgG1 Yes Yes 1.1 2.3
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FIGURE 2. Anti-EDA antibodies recognize epitopes on native EDA1. A, SDS-PAGE analysis and Coomassie Blue staining of 10 g/lane of the indicated
purifiedmouse IgG1monoclonal antibodies under reducing conditions. Migration positions of molecular mass standards (in kDa) are shown. B, Fc-EDA1 (200
or 50 ng) and Fc-hAPRIL (Fc-A, 500 ng) were resolved by Western blotting (WB) under reducing conditions and revealed with anti-human immunoglobulin
(anti-Fc), anti-EDA (Renzo2, EctoD1, EctoD2, or EctoD3), or anti-APRIL (Aprily2) antibodies.C, purified Fc-EDA1 and Fc-APRIL proteinswere coated directly in an
ELISA plate. Fc-EDA1 was also captured via the Fc portion using an anti-human antibody. Coated proteins were revealed with the indicated antibodies at the
indicated concentrations.
FIGURE 3. Sensitive detectionof Fc-EDA1 in serumby sandwich ELISA.A, sandwich ELISAs for Fc-EDA1were performedusing anti-EDA antibodies (Renzo2,
EctoD2, and EctoD3) at capture and biotinylated forms of the same antibodies for detection. Biotinylated antibodies were revealed with horseradish-coupled
streptavidin. B, comparison of sandwich ELISAs for Fc-EDA1 using EctoD2, EctoD3, EDAR-Fc, or anti-human immunoglobulin antibodies at capture and
biotinylated EcotD2, EctoD3, or horseradish-coupled goat anti-human (hu) immunoglobulin for revelation. C, comparison of sandwich ELISA (EctoD2 and
biotinylated EctoD3) for Fc-EDA1 in buffer or in the presence of 50%mouse or human serum.
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are characterized by reduced binding to EDAR and/or impaired
signaling capability (18). Renzo2 recognized wild type and
mutant Fc-EDA1 proteins equally well. EctoD2 and EctoD3
detected mutants Q358E or S374R with reduced intensity, sug-
gesting that these two amino acid residues are part of the
epitope (Fig. 4A). EctoD1 displayed the same general behavior
as EctoD2 and EctoD3, although with less sharp discrimination
between the different EDA mutant proteins (Fig. 4A). In the
crystal structure of EDA1 (38), Ser-374 andGln-358 are located
in the membrane-proximal portion of the TNF homology
domain, lining the predicted receptor-binding site on two adja-
cent EDA1 monomers (Fig. 4B). The recognition site of EDA1
by EctoD2 and EctoD3 is therefore predicted to overlap with
the receptor-binding site, suggesting that these antibodies may
interfere with receptor binding.
Blocking Anti-EDA Antibodies Inhibit EDA1 and EDA2 of
Mammalian and Avian Origin—The ability of anti-EDA anti-
bodies to inhibit EDA was first tested in a FACS-based assay in
which various Fc-EDA in conditioned medium, preincubated
or not with anti-EDA antibodies, were used to stain 293T cells
transfected with the extracellular domains of various EDA
receptors fused to the glycolipid anchor addition signal of
TRAILR3 (27). In this system, human and chicken Fc-EDA1
and Fc-EDA2 specifically stained cells transfected with their
cognate receptors (human or chicken EDAR or XEDAR) (Fig.
5A), but none of them bound to human or chicken TROY (Fig.
6). Although the anti-EDA EctoD1 and the control Aprily2
antibodies did not interfere with Fc-EDA staining, anti-EDA
antibodies EctoD2 and EctoD3 efficiently blocked the binding
of Fc-EDA1 to EDAR and of Fc-EDA2 to XEDAR in both
human and chicken systems (Fig. 5A). The inhibitory pattern is
consistent with (a) the location of epitopes recognized by
EctoD2 and EctoD3, (b) with the difference between mamma-
lian and chicken EDAbeing only three amino acids in the entire
C-terminal, receptor-binding region of EDA, and (c) with the
fact that, comparedwith EDA1, EDA2 lacks just two amino acid
residues within the receptor-binding sites (Fig. 7).
Blocking Anti-EDAAntibodies Inhibit Human EDA1 Binding
to EDAR at Close to Stoichiometric Ratio—The blocking activ-
ity of anti-EDA antibodies was also evaluated in an ELISA-like-
based assay, in which the binding of FLAG-tagged EDA1 to
coated EDAR-Fc was monitored after preincubation with or
without various anti-EDA antibodies. EctoD2 and EctoD3
decreased the binding signal, whereas Renzo2, EctoD1, and
Aprily2 did not (Fig. 5B). At the EC50 of inhibition, the ratio of
monomeric antibody to FLAG-tagged EDA1 trimer, assuming
amolecularmass of 150 kDa for the antibody and 59 kDa for the
EDA1 trimer, was 1.4 for EctoD2 and 1.1 for EctoD3, i.e., close
to stoichiometry (Table 2). It is noteworthy that the shape of the
curve obtained seems to indicate a more potent inhibition by
EctoD3 compared with EctoD2 (Fig. 5B).
Blocking Anti-EDA Antibodies Inhibit EDAR Activation in
Vitro and in Vivo—The inhibitory activities of anti-EDA anti-
bodieswere further evaluated in a functional assay, inwhich the
ability of Fc-EDA1 to trigger the apoptotic Fas pathway in a
surrogate reporter cell line expressing the EDAR-Fas fusion
receptor was assessed (14). EctoD2 and EctoD3 totally pro-
tected the reporter cells from Fc-EDA1-induced death when an
excess of inhibitory antibody was preincubated with Fc-EDA1
(Fig. 5C). The average ratio of antibody to hexameric Fc-EDA1
to achieve EC50 of inhibition at different antibody concentra-
tions, assuming a molecular mass of 262 kDa for the Fc-EDA1
hexamer, was 4.9 for EctoD2 and 2.3 for EctoD3 (Table 2).
Assuming that each antibody has two binding sites and each
Fc-EDA1 hexamer displays six epitopes, this corresponds to 1.6
and 0.8 antibody binding sites per epitope on Fc-EDA1.
The EDAR-Fas reporter cell line does not measure EDAR
signaling achieved through its native intracellular domain. To
investigatewhether anti-EDAantibodies could block the action
of EDA1 in a physiologically relevant context, Fc-EDA1 prein-
cubated with a 4-fold mass excess of either EctoD1 or EctoD2
was administered to newborn Eda-deficient mice, and the abil-
ity of Fc-EDA1 to induce development of tail hair and func-
tional sweat glands through activation of endogenous EDAR in
these animals wasmonitored (34). The EctoD1 antibody, which
did not block EDA receptor binding or function in vitro, did not
prevent Fc-EDA1 from rescuing ectodermal dysplasia symp-
toms as judged from the formation of tail hair and sweat glands
in these mice. The blocking antibody EctoD2, however, was
capable of completely suppressing the therapeutic effect of Fc-
EDA1 in this model (Fig. 8). Taken together, these results indi-
cate that the anti-EDA antibodies EctoD2 and EctoD3 inhibit
the action of EDA1 at close to stoichiometric ratio.
FIGURE 4. Anti-EDA antibodies EctoD2 and EctoD3 recognize epitopes overlapping the EDA receptor-binding site. A, Fc-EDA1 WT or containing the
indicated point mutations, or Fc-BAFF as a control, were coated onto ELISA plates and revealed with the indicated antibodies at the indicated concentration.
B, space filling representationof EDA1 structure (fromProteinDataBank coordinate file 1RJ7), showingoneof the EDA1monomers on the left (mono1) andone
on the right (mono 2). Positions of point mutants used in Fc-EDA1 of A are shown in black. The predicted binding site of EDAR is shown as a shade of gray
(receptor). In this representation, the membrane of the receptor-bearing cell would be at the bottom, and the collagen domain of EDA1 would be at the top.
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Blocking Anti-EDA Antibodies Induce Ectodermal Dysplasia
in DevelopingWild TypeMice—To assess whether EctoD2 and
EctoD3 can inhibit endogenous EDA1 and not only recombi-
nant EDA1 after preincubation, gravid wild type females were
administered either EctoD2 or EctoD3, or EctoD1 as a negative
control, at a dose of 4 mg/kg at regular intervals throughout
pregnancy. After birth, treatment was continued in half of the
pups and discontinued in the other half, and the phenotype of
pups was assessed after completion of development (at 3 weeks
and 1 month of age) (Figs. 9 and 10). Control wild type pups
treated with the non-blocking antibody EctoD1 were, as
expected, indistinguishable from untreated wild type mice
(Figs. 9 and 10). However, wild type mice exposed to the block-
ing antibodies EctoD2 or EctoD3 throughout development
closely resembled Eda-deficient Tabby mice with respect to
several characteristics: a total absence of guard hairs, the pres-
ence of a kink at the tail tip (however not as marked and more
“wavy” than in Eda-deficient mice), absence of hair in the ret-
roauricular region, thick and scaly eyelids with a semi-closed
eye phenotype, complete absence of functional sweat glands
and glandular tissue in footpads, small upper and lower molars
with a simplified cusp pattern compared with wild type, and a
total absence of mucus-secreting glands in the trachea and lipid-
secreting mebomian glands in eyelids (Figs. 9 and 10). Similar
results were obtained in pups where treatment with EctoD2 or
EctoD3 ceased at birth (Figs. 9 and 10). Therefore, wild type
FIGURE 5.Anti-EDAmonoclonal antibodies EctoD2 and EctoD3 inhibit mammalian and avian EDA1 and EDA2. A, receptors (human or chicken EDAR or
XEDAR) fused to the GPI anchor of TRAILR3 were expressed in 293T cells together with an EGFP tracer (x axis). Cells were stained with or without cell
supernatants containing Fc-EDA1 or Fc-EDA2 of human/mouse (human) or chicken origin (y axis). The interactions of Fc-EDAs with GPI-anchored receptors
were challenged by preincubation of the ligand with anti-EDA antibodies (EctoD1, EctoD2, and EctoD3) or with an irrelevant antibody (anti-APRIL). Both
scattergram axes show fluorescence intensity on a logarithmic scale (100–104). B, FLAG-EDA1 was diluted at the indicated concentrations and preincubated
with or without 125 ng/ml concentration of anti-EDA (Renzo2, EctoD1, EctoD2, or EctoD3) or anti-APRIL (Aprily2) monoclonal antibodies. The binding of
FLAG-EDA1 to coated EDAR-Fc protein was then probed by an ELISA-like assay. C, EDA1-sensitized Jurkat JOM2 EDAR-Fas reporter cells were incubated in the
presence of the indicated concentrations of Fc-EDA1, in the presence or absence of the indicated concentrations of anti-EDAmonoclonal antibodies EctoD1,
EctoD2, or EctoD3. Cell viability was determined by colorimetry (phenazine methosulfate/(3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium assay) and expressed as percentage of maximal survival.
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mice treated with blocking anti-EDA antibodies acquire a phe-
notype closely resembling that of Eda-deficient mice, with the
striking exception of tail hair that still developed in treated
mice, although these hairs were present with reduced density in
EctoD3-treated mice, where the frequency of antibody admin-
istration was higher (Figs. 9 and 10). Taken together, these
results indicate that administration of anti-EDA antibodies
EctoD2 or EctoD3 in developing wild type mice induces a phe-
notype of ectodermal dysplasia with almost all of the pheno-
typic characteristics observed in Eda-deficient mice.
DISCUSSION
The EDA pathway operates early in skin development, such
that its abolition bymutation results in the loss or altered devel-
opment of a range of cutaneous appendages. These early devel-
opmental roles of the EDA pathway are the most intensively
studied, in part because the lifelong morphological effects of
Eda mutation make it difficult to separate its developmental
roles from potential homeostatic roles in the adult. To enable
sensitive detection and effective suppression of EDA at any
developmental stage, we sought to generate function-blocking
anti-EDAmonoclonal antibodieswith broad species specificity.
The TNF homology domain of EDA is 100% conserved
across most mammals (Fig. 7). Antibodies against such con-
served, functional domains are usually easier to raise by immu-
nizing mutant animals that have never expressed the protein of
interest. Two anti-EDA antibodies obtained through this
approach inhibited EDA at an approximately 1:1 ratio, pointing
to their quality in this respect. In a sandwich ELISA, these anti-
bodies allowed sensitive detection of recombinant EDA in both
buffer and serum, which will be useful, for example to measure
distribution of the recombinant EDA protein undergoing clin-
ical trials.We identified two amino acid residues in EDAwhose
mutation partially reduced antibody binding. These residues
are most probably recognized on adjacent monomers of the
EDA trimer, on each side of the receptor-binding site, because
they would be too far apart if recognized within a single mono-
mer (Fig. 4B). Although EctoD2 and EctoD3 still recognized the
mutant versions of Fc-EDA by ELISA, it is noteworthy that we
selectively failed to purify thesemutants by affinity chromatog-
raphy with immobilized EctoD2 or EctoD3, whereas wild type
Fc-EDA and othermutants were readily purified on these affin-
ity columns (data not shown).
Ser-374 of EDA1, which is part of the epitope recognized by
both EctoD2 and EctoD3, is relatively close toGlu-308, which is
absent in the EDA2 splice form, and Tyr-343, which is substi-
tuted with a phenylalanine residue in EDAs of avian origin. The
closeness of these sequence differences to the epitope raised the
question of whether these antibodies would recognize EDA2
and avian EDA (Figs. 5 and 6). In fact, antibodies EctoD2 and
EctoD3 effectively inhibited EDA1 and EDA2 of human and
bird origin. These antibodies can thus probably be used to study
EDA function in a wide range of species not necessarily easily
amenable to genetic manipulations. Of particular relevance,
chicken is used as amodel for the study of feather development,
and EDA is involved in this process (39, 40). Based on the care-
ful sequence analysis of EDA, EDAR, XEDAR, and TROY in
various species, it has been hypothesized that TROY might be
the receptor for EDA2 in vertebrates, with the exception of
therians (i.e., marsupials and placental mammals) where the
specificity of EDA2 would have shifted to XEDAR. Indeed, the
substitution of Phe-343 (in birds and other tetrapods) by Tyr-
343 (in therians) correlates with important sequence differ-
ences in XEDAR and TROY within the (putative) EDA2-bind-
ing region (41). However, the direct demonstration of the
interaction of EDA2 with XEDAR (and not TROY) using
chicken proteins goes against this hypothesis and rather sug-
gests that EDA2 binding to XEDAR is conserved across the
vertebrates.
To achieve in vivo effects, blocking antibodies should not
only inhibit EDA but also be able to penetrate relevant tissues
during the stages at which this signal is active. In the experi-
ments described here, which tested the ability of the antibodies
to reproduce the developmental effects of EDA signal ablation,
this critical timewindowwas through embryonic development.
Youngmammals need some time after birth until they can pro-
duce their own protecting antibodies, for example against com-
mon bacteria epitopes. In the meantime, they acquire the spec-
trum of antibodies present in maternal serum by one or both of
the following ways: (a) in utero transplacental antibody trans-
FIGURE 6. Receptor binding specificity of human and chicken EDA1 and
EDA2. Receptors (human or chicken EDAR, XEDAR, or TROY) fused to the GPI
anchor of TRAILR3 were expressed in 293T cells together with an EGFP tracer
(x axis). Cells were stained with cell supernatants containing human or
chicken Fc-EDA1or Fc-EDA2. ExpressionofGPI-anchored receptorswasmon-
itoredwith amonoclonal antibody (mAb572) recognizing theC-terminal por-
tion of TRAILR3 present in all receptors. Both scattergram axes show fluores-
cence intensity on a logarithmic scale (100–104).
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port (active in humans but less efficient inmice (42)) and/or (b)
postnatal import of maternal antibodies present in milk via an
antibody transport system in the gut epithelium (active in mice
but less in humans) (42, 43). The induction of an Eda-deficient
phenotype in pups of wild type mothers receiving antibodies
intravenously shows that enough antibody was transported to
inhibit the developmental function of EDA at relatively early
time points, because EDAR expression in the oral epithelium
starts at embryonic day 10 (7).
Although wild typemice exposed to blocking anti-EDA anti-
bodies acquired an Eda-deficient phenotype, tail hair forma-
tion was not fully abrogated. This cannot be explained by an
insufficient amount of systemic antibody at the onset or end of
treatment because guard hairs, which develop before tail hairs,
were inhibited, and so were sweat glands that can be induced at
the same time or even after tail hair (34). We can also rule out
the hypothesis that tail hair can form independently of EDA1
and EDAR, because both Eda-deficient and Edar-deficient
mice lack tail hair (21). We rather hypothesize that blocking
anti-EDA antibody levels have dropped below the efficacy
threshold in tail tissue of the developing mice during a short
period of time. Tail hair formation in Eda-deficient mice can
indeed take place upon exposure to active EDA for a period as
short as 4 h (14). It is also possible that access of the antibody to
tail tissue is more difficult than to other parts of the body.
There are at least two possible explanations for the origin
of the kink at the tip of the tail of Tabby mice. On the one
hand, in the absence of hair and hair-associated skin stem
FIGURE 7. TNF homology domain alignment of EDA1 from various species. A, scientific and common names of the various species are indicated on the
left-hand sides of the top and bottomparts of the alignment, respectively. The two amino acid residues absent in EDA2 are indicated at the top of the sequence.
B, space filling representationof EDA1 structure (fromProteinDataBank coordinate file 1RJ7) asdescribed in the legend toFig. 3B, but highlighting theposition
of amino acid residues differing between human and chicken EDA. The location of Glu-308 that is present in EDA1 but not in EDA2 is also shown.
FIGURE 8. Anti-EDAmonoclonal antibody EctoD2 blocks the therapeutic
activity of Fc-EDA in vivo.Wild type or Eda-deficient Tabby mice were ana-
lyzed at weaning (3 weeks old) for the presence or absence of hair on the tail
and functional sweat glands in footpads using a starch-iodine sweat assay.
Eda-deficient mice were either left untreated or treated on the day of birth
with Fc-EDA1 at 2.5 mg/kg that had been preincubated with a 4-fold mass
excess of either EctoD1 (n 3) or EctoD2 (n 4) monoclonal antibodies, as
indicated. All mice in a treatment group displayed identical phenotypes.
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cells, tail skin growth is impaired (44). This suggests that
kink formation could result from a compression of the form-
ing vertebrae by the skin that is too tight. On the other hand,
bone density is reduced in epiphysis of Eda-deficient verte-
bra (45), a defect that may participate to kink formation.
Here, we observe that mice treated with anti-EDA antibodies
FIGURE 9.Anti-EDAmonoclonal antibodies EctoD2 and EctoD3, but not EctoD1, induce ectodermal dysplasia when administered during embryonic
development inwild typemice. Pregnantwild typemicewere treated intravenously every second or fourth daywith EctoD1 (E0, E2, E4, E6, E8, E10, E12, E14,
E16, and E18[P1, P2, P4, P6, P8, P10, P14, P16, and P18]), EctoD2 (E5, E9, E12, and E16[P2, P6, P10, P14, and P16]), or EctoD3 (E3, E5, E8, E10, E12, E14, E16,
and E18[P1, P3, P5, P7, P9, P11, P13, P15, P17, and P19]) at 4mg/kg throughout pregnancy. Treatmentwas stopped at birth in half of the pups and continued
in theotherhalf of thepupsat the samedoseup to theageof 16–19days. All pupswereanalyzedat 3weeksof age for their external appearanceandat 1month
for necropsy. Untreatedwild type and Eda-deficient Tabbymice were similarly analyzed for comparison. The figure shows results for one animal per group.
Phenotype within a group was very similar or identical. Treatment EP, treatment was performed during embryogenesis and continued postbirth by
intraperitoneal injections in pups. Treatment E, treatment was performed during the embryogenesis only, and pups did not receive intraperitoneal
injections postbirth. A, back hair with protruding guard hairs. B, tail hair phenotype. C, phenotype of the tip of the tail.D, top view of the retroauricular region.
E, eye phenotype. F, footpads with functional sweat glands visualized as black dots (arrowheads) with the starch iodine test. G, lower molars, with the anterior
part on the top. H, upper molars, with the anterior part on the top. I, sections of footpads with glandular structures of sweat glands (arrowhead), stained with
hematoxylin and eosin. J, sections of the trachea stained with Alcian blue to reveal mucus-secreting glands (arrowheads). K, eyelid sections stained with
hematoxylin and eosin, with glandular structure of meibomian glands (arrowheads).
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develop a Tabby phenotype, with the exception of the hairy
tail. The observation that these mice have attenuated kinks
fits well with the hair-dependent skin growth model but also
suggests that additional, vertebra-intrinsic EDA defects may
be at play in the genesis of kinks.
Mice in which treatment with the EDA blocking antibody
was interrupted after the in utero period displayed a phenotype
as severe as those in which treatment was continued post birth.
Because it is known that sweat glands can be induced after birth
(34), this indicates that half-life of the antibodies is long enough
to cover this phase or that it has been transferred postbirth from
mother to pups via milk.
Blocking anti-EDA antibodies will be useful to investigate
postdevelopmental functions of EDA andmay open the way for
applications in adults. Eda-deficient mice overexpressing an
Eda1 transgene throughout development displayed correc-
tion of several ectodermal defects and developed a pheno-
type of sebaceous gland hyperplasia (9). Sebaceous gland size
was normalized following inducible shutdown of the trans-
gene in adult mice, indicating a likely trophic (non-develop-
mental) role for EDA in the regulation of sebaceous gland
size (9). Inhibition of EDA might therefore be beneficial in
conditions with deregulated glandular activity, such as acne
or seborrhea.
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FIGURE 10.Anti-EDAmonoclonal antibodies EctoD2 and EctoD3 induce ectodermal dysplasiawhen administered during embryonic development in
wild typemice. Some of the parameters shown in Fig. 9were quantified.Mice treated in utero andmice treated in utero and postbirthwith the same antibody
were pooled for the analysis, except for mice treated with the anti-EDA antibody EctoD3 in the analysis of tail hair. A, number of guard hairs visible in pictures
similar to those shown in Fig. 9A, as a function of genotype and treatment. B, tail hair score, according to the following scoring system (30): score 0, no hair (like
in Eda-deficient mice); score 1, sparse hair on the lower face of the tail; score 2, dense hair on the lower face of the tail; score 3, dense hair on both faces of the
tail; score4, verydensehair (likewild type). Eachdot represents amouse.C, tail kink score.Abroken linewasdrawnonpicturesof the tail tip (suchas those shown
in Fig. 9C), and the sumof the angleswas plotted as a function of genotype and treatment.D, the bald area behind the earswas delimitedmanually onpictures
similar to those of Fig. 9D, and the surface area of these regions was quantified using ImageJ. E, the width and height of the eye opening was measured on
pictures similar to those of Fig. 9E. The height to width ratio was plotted as a function of genotype and treatment. F, the length of the first lowermolar and the
length of lower molars 1, 2, and 3 taken together was measured in pictures similar to those of Fig. 9G. The ratio between these distances was calculated.
Measures were taken on both lower jaw quadrants. Treatment sometimes resulted in the absence of a third molar, as can sometimes be observed in
Eda-deficientmice. Quadrants lacking the thirdmolarwere excluded form the analysis (onequadrant for embryonic treatmentwith EctoD2 and twoquadrants
for embryonic and postbirth treatment with EctoD3). The numbers of mice were as follows: Eda-deficient (Eda-def): n 5; wild type (wt): n 5; wt anti-EDA
EctoD1: n 4; wt anti-EDA EctoD2: n 6; wt anti-EDA EctoD3: n 9 (n 4 for continuous treatment (EP) and n 5 for in utero treatment only (E)).
Means standard deviation are shown. **, p value 0.005, as determined with Student’s t test.
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